Htc Corporation v. Ipcom Gmbh & Co., Kg

• Court: District Court, District of Columbia
• Decided: December 3, 2009
• Docket: Civil Action No. 2008-1897
• Status: Published

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

) HTC CORPORATION, et al., ) ) Plaintiffs and, ) Counterclaim-Defendants, ) v. ) Civil Action No. 08-1897 (RMC) ) IPCOM GMBH & CO., KG, ) ) Defendant and ) Counterclaim-Plaintiff. ) )

MEMORANDUM OPINION

Defendant and Counterclaim-Plaintiff IPCom Gmbh & Co. (“IPCom”), KG, moves

to dismiss the inequitable conduct counterclaims and to strike the inequitable conduct affirmative

defenses asserted by Plaintiffs and Counterclaim-Defendants HTC Corporation and HTC America,

Inc. (collectively “HTC”). IPCom contends that HTC fails to plead inequitable conduct with the

particularity required by Federal Rule of Civil Procedure 9(b) and Exergen Corporation v. Wal-Mart

Stores, Inc., 575 F.3d 1312 (Fed. Cir. 2009). The Court will grant the motion in part and deny it in

part.1

I. FACTS

This is a patent dispute in which HTC seeks a declaration that it does not infringe

IPCom’s U.S. Patent No. 5,390,216 (“’216 Patent”), titled Synchronization Method of a Mobile

Radiotelephone. IPCom already has sued HTC under German patent law based on the German

1 Resolution of this motion to dismiss does not address or portend resolution of the pending motion to apply German law. counterpart to the ’216 Patent, among others.2 IPCom responded to HTC’s complaint by filing

counterclaims asserting that HTC violates its ’216 Patent and two others owed by IPCom, U.S.

Patent No. 7,043,751 (“’751 Patent”), titled Method of Allocating Access Rights to a

Telecommunications Channel to Subscriber Stations of a Telecommunications Network and

Subscriber Station, and U.S. Patent No. 6,879,830 (“’830 Patent”), titled Method for Handover,

Mobile Station for Handover and Base Station for Handover. HTC answered the counterclaims and

asserted, among others, an affirmative defense that the three Patents, for differing reasons, are

unenforceable due to inequitable conduct. See Pl.’s Am. Answer ¶¶ 40-82. The same allegations

are contained in HTC’s counterclaims. Id. at 20 (Declaratory Judgment Counterclaims). IPCom has

filed a motion to dismiss all allegations of inequitable conduct; in response, HTC has withdrawn its

Sixth Affirmative Defense regarding the unenforceability of the ’216 Patent. See HTC’s Opp’n to

IPCom’s Mot. to Dismiss (“HTC’s Opp’n”) [Dkt # 87] at 1, n.1.

II. LEGAL STANDARDS

A. Heightened Pleading Under Federal Rule 9(b)

IPCom’s argument that HTC’s counterclaims fail to state a claim upon which relief

can be granted is based on its belief that HTC has failed to satisfy the heightened requirements for

pleading fraud as set forth in Federal Rule of Civil Procedure 9(b). While Rule 8 requires that every

complaint include “a short and plain statement of the claim showing that the pleader is entitled to

relief” and that “each averment of a pleading be simple, concise, and direct,” Fed. R. Civ. P. 8(a),

2 See Pl.’s and Counterclaim-Def.’s Am. Answer & Declaratory J. Countercls (“Pl.’s Am. Answer”) [Dkt. # 60] at 3, ¶ 21 (“HTC admits that in April 2008, IPCom initiated proceedings in Germany against HTC Corporation for infringement of the European counterparts of the ’216 patent and the ’751 patent, and IPCom initiated proceedings against certain wireless service providers for using HTC phones in violation of the European counterparts of the ’216, ’751 and ’830 patents.”).

-2- Rule 9(b) requires any party alleging fraud or mistake to “state with particularity the circumstances

constituting fraud or mistake. Malice, intent, knowledge, and other conditions of a person’s mind

may be alleged generally.” Fed. R. Civ. P. 9(b). These rules are not contrary to one another, but

should be read in conjunction. United States ex rel. Williams v. Martin-Baker Aircraft Co., 389 F.3d

1251, 1256 (D.C. Cir. 2004).

The Federal Circuit has held that “in pleading inequitable conduct in patent cases,

Rule 9(b) requires identification of the specific who, what, when, where, and how of the material

misrepresentation or omission committed before the PTO.” Exergen Corp. v. Wal-Mart Stores, Inc.,

575 F.3d 1312, 1327 (Fed. Cir. 2009). Also, while Rule 9 allows “[m]alice, intent, knowledge, and

other conditions of a person’s mind [to] be alleged generally,” “‘generally’ is a relative term. In the

context of Rule 9, it is to be compared to the particularity requirement applicable to fraud or mistake.

Rule 9 merely excuses a party from pleading discriminatory intent under an elevated pleading

standard.” Ashcroft v. Iqbal, 129 S. Ct. 1937, 1954 (2009). “Pleading on ‘information and belief’

is permitted under Rule 9(b) when essential information lies uniquely within another party’s control,

but only if the pleading sets forth the specific facts upon which the belief is reasonably based.”

Exergen, 575 F.3d at 1330.

B. The Patent Application Process

An application for a patent must be submitted to the Director of the United States

Patent and Trademark Office (“PTO”). 37 C.F.R. § 1.51(a). A complete patent application includes:

a specification including one or more claims; an oath or declaration that the applicant believes

himself to be the original inventor of the process or invention to be patented; drawings, if necessary;

and the “prescribed filing fee, search fee, examination fee, and application size fee.” 37 C.F.R. §

-3- 1.51(b); see 35 U.S.C. §§ 112 & 115. A claim specification must contain a written description of

the invention to be patented and the process of making and using it, in “full, clear, concise, and exact

terms” such that any person skilled in the art to which it pertains could make and use it. 35 U.S.C.

§ 112. The claim or claims included in the specification must point out the specific subject matter

which the applicant believes is his invention. Id.

“Individuals associated with the filing and prosecution of a patent application,” as

such persons are defined in 37 C.F.R. § 1.56(c), have a duty to disclose to the PTO any information

material to the “patentability” of their claims. Id. § 1.56.

A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. . . . The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) or 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct.

Id. § 1.56(a) (emphases added). “A breach of [the duty of candor and good faith], which breach can

include affirmative misrepresentations of material facts, failure to disclose material information, or

submission of false material information, coupled with an intent to deceive, constitutes inequitable

conduct” and can render a patent unenforceable. Li Second Family L.P. v. Toshiba Corp., 231 F.3d

1373, 1378 & 1381 (Fed. Cir. 2000).

Information is material if it tends to prove that the applicant’s claim is unpatentable

-4- or challenges a position the applicant takes in asserting the patentability of his claim. 37 C.F.R. §

1.56(b). “The threshold showing of materiality . . . can be met by showing a reasonable examiner

would have considered such information important in deciding whether to allow the application.”

Aventis Pharma S.A. v. Amphastar Pharms., Inc., 176 Fed. Appx. 117, 119-20 (Fed. Cir. 2006)

(citing Digital Control, Inc. v. Charles Mach. Works, 437 F.3d 1309, 1316 (Fed. Cir. 2006)); Molins

Plc v. Textron, 48 F.3d 1172, 1179 (Fed. Cir. 1995) (“[T]he standard to be applied in determining

whether a reference is ‘material’ is not whether the particular examiner of the application at issue

considered the reference to be important; rather, it is that of a ‘reasonable examiner.’”). However,

information is not considered “material to patentability,” and is therefore not subject to disclosure,

when it is cumulative of information already included in the record of the patent prosecution. See

37 C.F.R. § 1.56(b); Star Sci., Inc. v. R.J. Reynolds Tobacco Co., 537 F.3d 1357, 1367 (Fed. Cir.

2008) (“It is well-established, however, that information is not material if it is cumulative of other

information already disclosed to the PTO.”).

III. ANALYSIS

As to the ’830 and ’751 Patents, HTC basically alleges that the patent applicants

failed to disclose material prior art to the PTO and thus committed fraud on the PTO. IPCom retorts

that Exergen tightened the standards for pleading inequitable conduct under Federal Rule of Civil

Procedure 9(b) and that HTC’s pleadings fail under the new standards.

A. ’830 Patent

HTC argues that during the prosecution of the German application that corresponds

to the ’830 Patent, the European Patent Office issued a search report identifying a prior art U.S.

patent and concluded that the claims of the corresponding German application lacked novelty over

-5- the identified prior art. Because the patent applicants for the ’830 Patent in the United States failed

to disclose this prior art, they allegedly violated 37 C.F.R. § 1.56 (Rule 56 of the PTO) and thereby

committed fraud.

However, without regard to the effect of Exergen on this area of patent law, the PTO

already has reexamined the ’830 Patent and rejected HTC’s argument. On July 21, 2009, the PTO

found that the “McDonald Patent” — the prior art reference identified by HTC in connection with

the ’830 Patent — is cumulative and fails to raise new issues. Thus, “a reasonable examiner would

not consider the teachings of the McDonald patent important in deciding to allow the claims being

considered.” Def.’s Request for Judicial Notice [Dkt. # 69], Ex. H at 10 (PTO Decision Granting

Reexamination at 8) (emphasis in original).3 The fact that the European Patent Office concluded that

the McDonald Patent was material cannot make the patent applicants’ failure to submit it in

connection with the ’830 Patent in the United States a fraud, when the PTO has found it merely

cumulative of other available and submitted information. The PTO concluded that “[i]t is not agreed

that McDonald raised a [substantial new question] of patentability as to claims 1-18 of the [’830]

patent. Particularly, McDonald fails to teach those significant limitations discussed above, thus

McDonald is cumulative, thereby also failing to raise any new issues.” Id.

There is no fraud when a missing reference is merely cumulative. See 37 C.F.R. §

1.56(b); Star Sci., Inc., 537 F.3d at 1367. HTC’s counterclaim and affirmative defense that

inequitable conduct renders the ’830 Patent unenforceable will be dismissed and stricken.

3 The Court takes judicial notice of the PTO pleadings. A court may take judicial notice of court documents and other public records. See Covad Comms. Co. v. Bell Atlantic Corp., 407 F.3d 1220, 1222 (D.C. Cir. 2005) (permitting judicial notice of facts in public records of other proceedings); Jane Does I Through III v. District of Columbia, 238 F. Supp. 2d 212, 216-17 (D.D.C. 2002) (court may take judicial notice of public records of prior litigation).

-6- B. ’751 Patent

As to the ’751 Patent, HTC’s Amended Answer and Counterclaims identify three

precise standards documents as the prior art that was not submitted to the PTO. See Am. Answer

¶ 58. HTC specifically accuses certain named inventors of the ’751 Patent, id. ¶ 52, and explains

where, when, and how these inventors allegedly became aware of the documents that were withheld

from the PTO. Id. ¶¶ 59-60. These allegations clearly provide sufficient notice to IPCom to allow

it to prepare its defense. Furthermore, HTC has satisfied Exergen’s “who, what, when, where, and

how” standard with respect to pleading inequitable conduct. Exergen, 575 F.3d at 1327 (noting that

it was “following the lead of the Seventh Circuit in fraud cases, [and . . .] hold[ing] that in pleading

inequitable conduct in patent cases, Rule 9(b) requires identification of the specific who, what, when,

where, and how of the material misrepresentation or omission committed before the PTO”). HTC

also has met Exergen’s requirement that when a party makes allegations on information and belief,

its beliefs are reasonably supported by facts. Exergen, 575 F.3d at 1330. For example, HTC alleges,

on information and belief, that “the GSM 04.60 standards were also known to [two named inventors

of the patent]” and explains the basis for this belief — these standards were referenced in a meeting

at which at least one inventor was listed as a participant. Am. Answer ¶ 60. Thus, HTC’s claims

fully comport with Rule 9(b).

IPCom seeks to avoid this conclusion by arguing that the prior art references are

lengthy and HTC has not proven that the named inventors read the particular pages of the standards

documents that are relevant. Such arguments, however, confuse the burdens of proof at trial with

the pleading requirements of Rule 9(b). See Bartronics, Inc. v. Power-One, Inc., 245 F.R.D. 532,

537 n.3 (S.D. Ala. 2007) (patentee’s motion to dismiss accused infringer’s inequitable conduct

-7- pleadings were denied in part because “[w]hile Bartronics is correct that defendants must prove

knowledge and intent at trial in order to prevail on this theory of relief, they are under no obligation

to make such an onerous showing at the pleadings stage. Plaintiff’s argument confuses these very

distinct burdens.”). While Bartronics preceded Exergen, the Court does not read Exergen to have

affected its analysis. PTO Rule 56 is still on the books and addresses the possibility that a patent

applicant may unfairly obtain a patent because it hid prior art from the PTO. Exergen adopted a

heightened pleading standard, fully met by HTC’s pleadings concerning the ’751 Patent; it did not

otherwise alter the burdens of proof. Therefore, IPCom’s motion to dismiss and strike HTC’s

inequitable conduct counterclaims and affirmative defenses regarding the ’751 Patent will be denied.

IV. CONCLUSION

For the reasons stated above, the pending motion to dismiss and strike HTC’s

inequitable conduct counterclaims and affirmative defenses [Dkt. # 67] will be granted in part and

denied in part. The motion is conceded as to the ’216 Patent, will be granted as to the ’830 Patent,

and will be denied as to the ’751 Patent. A memorializing order accompanies this memorandum

opinion.

Date: December 3, 2009 /s/ ROSEMARY M. COLLYER United States District Judge

-8-